Voleon Capital Management’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$261K Sell
12,304
-74,138
-86% -$1.48M 0.01% 690
2025
Q4
$1.41M Sell
86,442
-219,659
-72% -$3.32M 0.03% 387
2025
Q3
$3.58M Buy
306,101
+130,094
+74% +$1.7M 0.09% 231
2025
Q2
$2.04M Buy
176,007
+78,856
+81% +$719K 0.11% 174
2025
Q1
$848K Buy
97,151
+82,857
+580% +$1.04M 0.07% 221
2024
Q4
$205K Buy
+14,294
New +$226K 0.02% 313

Other funds holding TXG

Voleon Capital Management's TXG Position: Q1 2026 in Review

Voleon Capital Management reduced its 10x Genomics (TXG) stake by 86% in Q1 2026, selling an estimated $1.48M and leaving 12,304 shares worth $261K. The position accounts for 0.01% of the portfolio, ranked #690.

Voleon Capital Management first reported a position in TXG in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.58M in Q3 2025. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Voleon Capital Management held 12,304 shares of 10x Genomics worth $261K as of Q1 2026.
  • Voleon Capital Management sold 74,138 10x Genomics shares in Q1 2026, an estimated $1.48M.
  • 10x Genomics made up 0.01% of Voleon Capital Management's portfolio in Q1 2026, its #690 holding.
  • Voleon Capital Management first reported a position in 10x Genomics in Q4 2024 and has held it in 6 quarters since.
  • Voleon Capital Management's 10x Genomics position peaked at $3.58M in Q3 2025.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.